H5N1 News and Research

Latest H5N1 News and Research

Avian influenza A H3N8 virus poses threat to humans

Avian influenza A H3N8 virus poses threat to humans

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

CDC closes labs after anthrax, flu accidents

CDC closes labs after anthrax, flu accidents

First Edition: July 14, 2014

First Edition: July 14, 2014

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

Biotech to the rescue

Biotech to the rescue

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists map key elements of immune overreaction triggered by influenza virus infection

TSRI scientists describe severe immune overreaction caused by flu infections

TSRI scientists describe severe immune overreaction caused by flu infections

Upstream interventions may provide options to contain emerging pathogens at source

Upstream interventions may provide options to contain emerging pathogens at source

New study tracks spread of H5N1 variant in Egypt recently identified as major epicenter for virus

New study tracks spread of H5N1 variant in Egypt recently identified as major epicenter for virus

Chinese scientists confirm world’s first case of human infection with new avian influenza virus

Chinese scientists confirm world’s first case of human infection with new avian influenza virus

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

ATS Labs offers testing of antimicrobial products for efficacy against H7N9 virus

ATS Labs offers testing of antimicrobial products for efficacy against H7N9 virus

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.